L‐leucine improves anemia and growth in patients with transfusion‐dependent Diamond‐Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond‐Blackfan Anemia Registry. Issue 12 (6th October 2020)

• Record Type: Journal Article
• Authors: Vlachos, Adrianna; Atsidaftos, Evangelia; Lababidi, Mohammad Lutfi; Muir, Ellen; Rogers, Zora R.; Alhushki, Waseem; Bernstein, Jonathan; Glader, Bertil; Gruner, Barbara; Hartung, Helge; Knoll, Christine; Loew, Thomas; Nalepa, Grzegorz; Narla, Anupama; Panigrahi, Arun R.; Sieff, Colin A.; Walkovich, Kelly; Farrar, Jason E.; Lipton, Jeffrey M.
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 12(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-10-06
• Subjects: clinical trial -- Diamond‐Blackfan anemia -- erythropoiesis -- L‐leucine; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28748
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Diamond‐Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by anemia, short stature, congenital anomalies, and cancer predisposition. Most cases are due to mutations in genes encoding ribosomal proteins (RP) leading to RP haploinsufficiency. Effective treatments for the anemia of DBA include chronic red cell transfusions, long‐term corticosteroid therapy, or hematopoietic stem cell transplantation. In a small patient series and in animal models, there have been hematologic responses to L‐leucine with amelioration of anemia. The study objectives of this clinical trial were to determine feasibility, safety, and efficacy of L‐leucine in transfusion‐dependent patients with DBA. Procedure: Patients ≥2 years of age received L‐leucine 700 mg/m 2 orally three times daily for nine months to determine a hematologic response and any improvement in growth (NCT01362595). Results: This multicenter, phase I/II study enrolled 55 subjects; 43 were evaluable. There were 21 males; the median age at enrollment was 10.4 years (range, 2.5‐46.1 years). No significant adverse events were attributable to L‐leucine. Two subjects had a complete erythroid response and five had a partial response. Nine of 25, and 11 of 25, subjects experienced a positive weight and height percentile change, respectively, at the end of therapy. Conclusions: L‐leucine is safe, resulted in an erythroid response in 16% of subjects with DBA, and led to an increase in weight and linear growth velocity in 36% and 44% of evaluable subjects, respectively. Further studies will be critical to understand the role of L‐leucine in the management of patients with DBA.